Alnylam Pharmaceuticals Inc $ 146.7 1.1 (0.76%)
Volume:
4,708
Avg Vol (1m):
480,659
Market Cap $:
17.01 Bil
Enterprise Value $:
15.40 Bil
P/E (TTM):
0.00
P/B:
12.12
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.11 | ||
| Equity-to-Asset | 0.42 | ||
| Debt-to-Equity | 0.23 | ||
| Debt-to-EBITDA | -0.39 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 3.37 | ||
| Beneish M-Score | 2.13 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -267.51 | ||
| Net Margin % | -245.14 | ||
| ROE % | -56.02 | ||
| ROA % | -31.79 | ||
| ROC (Joel Greenblatt) % | -137.42 | ||
| 3-Year Revenue Growth Rate | 54 | ||
| 3-Year EBITDA Growth Rate | -19.2 | ||
| 3-Year EPS without NRI Growth Rate | -19.2 |
ALNY
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 12.12 | ||
| PS Ratio | 47.74 | ||
| EV-to-EBIT | -17.6 | ||
| EV-to-EBITDA | -18.96 | ||
| EV-to-Revenue | 44.62 | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 5.42 | ||
| Days Inventory | 428.62 | ||
| Days Sales Outstanding | 73.08 | ||
| Days Payable | 188.38 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 12.12 | ||
| Price-to-Median-PS-Value | 0.54 | ||
| Earnings Yield (Greenblatt) % | -5.68 |